Glioma
Conditions
Keywords
glioma, ANXA2 Expression, periatumoral edema zone
Brief summary
The prognostic value of ANXA2 expression in tumor tissue and PTBE was analyzed, so as to seek new therapies to inhibit glioma invasion and improve the prognosis of glioma patients
Detailed description
The main reason for the poor prognosis of glioma is the invasion of tumor cells along the extracellular space (ECS) in the periatumoral edema zone (PTBE).Previous studies have shown that ANXA2 is highly expressed in glioma and promotes tumor growth and invasion, while its expression in the PTBE microenvironment of glioma and its mechanism of action on tumor invasion have not been reported.Previous study found that ANXA2 was overexpressed in gliomas and was associated with poor prognosis, and the low expression of ANXA2 significantly inhibited tumor invasion in vitro.Relevant studies have also confirmed that as an exocrine protein, it mainly plays a role in ECS, and it has previously been carried out on the tissue structure of ECS in tumor microenvironment.Therefore, investigators planned to study the mechanism of ANXA2 expression in PTBE microenvironment ECS on tumor invasion.This project aims to take glioma related issues as the research object and analyze tumor tissue and tumor tissue
Interventions
DIAGNOSTIC_TESTexpression level of ANXA2 protein
The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
Sponsors
Peking University Third Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have undergone microneurosurgical resection of the tumor in our hospital and are pathologically confirmed to be supratentorial glioma; * Preserving the remaining tissue samples of paired gliomas and PTBE for pathological examination; * The patients agreed to be enrolled and signed the informed consent; * The clinical data of the patients are complete and not lost; * No serious complications occurred after surgery.
Exclusion criteria
* All glioma patients who did not meet the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From the date of surgery to the date of death from any cause, assessed up to 18 weeks. | Follow-up information was collected by telephone follow-up and regular review when patients returned to the hospital. Telephone follow-up was conducted every 3 months, and the main follow-up content was survival time, and the end point of follow-up was to the patient's death |
Countries
China
Contacts
Primary ContactYang Jun
Backup ContactChen Xin
Outcome results
None listed